C
Christian A. Lerchenmuller
Researcher at Praxis
Publications - 42
Citations - 2678
Christian A. Lerchenmuller is an academic researcher from Praxis. The author has contributed to research in topics: FOLFIRI & Bevacizumab. The author has an hindex of 13, co-authored 41 publications receiving 2235 citations.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Sebastian Stintzing,Sebastian Stintzing,Dominik Paul Modest,Dominik Paul Modest,Lisa Rossius,Markus M. Lerch,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Swantje Held,Clemens Giessen-Jung,Markus Moehler,Andreas Jagenburg,Thomas Kirchner,Thomas Kirchner,Andreas Jung,Andreas Jung,Volker Heinemann,Volker Heinemann +27 more
TL;DR: The FIRE-3 trial as discussed by the authors compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRi plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
Susanna Hegewisch-Becker,Ullrich Graeven,Christian A. Lerchenmuller,B. Killing,Reinhard Depenbusch,Claus-Christoph Steffens,Salah-Eddin Al-Batran,Thoralf Lange,Georg Dietrich,Jan Stoehlmacher,Andrea Tannapfel,Anke Reinacher-Schick,Julia Quidde,Tanja Trarbach,Axel Hinke,Hans-Joachim Schmoll,Dirk Arnold +16 more
TL;DR: This open-label, non-inferiority, randomised phase 3 trial investigated whether no continuation of therapy or bevacizumab alone are non- inferior to fluoropyrimidine plus bevacsumab, following induction treatment with a fluoropyridine plus oxaliplatin plus beVacizumsab.
Journal ArticleDOI
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Sebastian Stintzing,Pratyaksha Wirapati,H. J. Lenz,Daniel Neureiter,L. Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Florian Kaiser,S-E. Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Markus Moehler,Werner Scheithauer,Swantje Held,Dominik Paul Modest,Andreas Jung,T. Kirchner,Dan Aderka,Sabine Tejpar,Volker Heinemann +22 more
TL;DR: CMS classification provides deeper insights into the biology to CRC, but at present time has no direct impact on clinical decision-making.
Journal ArticleDOI
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg,Walter L. Vervenne,Maria De Santis,Ludwig Fischer von Weikersthal,Peter J. Goebell,Christian A. Lerchenmuller,Uwe Zimmermann,Monique M.E.M. Bos,W. Freier,Silke Schirrmacher-Memmel,Michael Staehler,Sascha Pahernik,Maartje Los,Marcus Schenck,Anne Flörcken,Cornelis Van Arkel,Kirsten Hauswald,Martin Indorf,Dana Gottstein,Maurice Stephan Michel +19 more
TL;DR: Results demonstrate that sorafenib followed by sunitinib and vice versa provide similar clinical benefit in mRCC, and both treatment options were similarly effective in patients with advanced/metastatic kidney cancer.